-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13

Benzinga·07/21/2026 12:43:46
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.